7AL0 Stock Chart & Stats
€0.04
>-€0.01(-2.56%)
At close: 4:00 PM EDT
€0.04
>-€0.01(-2.56%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.09
Previous CloseN/A
Volume748.00
Average Volume (3M)3.35K
Market Cap
€3.24M
Enterprise Value-€907.86K
Total Cash (Recent Filing)€41.25M
Total Debt (Recent Filing)€27.78M
Price to Earnings (P/E)―
Beta-106.17
Next Earnings
Feb 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding3,568,107,000
10 Day Avg. Volume6,678
30 Day Avg. Volume3,353
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.35
Price to Sales (P/S)18.04
P/FCF Ratio-0.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.11
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Oncology PlatformA focused antibody-immunotherapy strategy gives Alligator a coherent development platform spanning research, preclinical work, and clinical trials. Concentrating resources on cancer treatment mechanisms may support specialized expertise and create multiple opportunities for advancing candidates over the medium term.
Partnering-Based Funding ModelThe partnering model can provide non-linear value creation if candidates attract larger pharmaceutical collaborators, combining potential upfront and milestone funding with longer-term royalties. This structure may help monetize research capabilities before internally commercializing a product.
Reduced LossesA reduction in losses relative to 2023–2024 indicates some improvement in the recent cost or expense profile, even though the company remains far from profitable. If maintained, this could slow resource consumption and extend the period available to advance clinical assets.
Bears Say
Shrinking RevenueVery low and declining revenue shows that the company has not yet established a dependable commercial income base. Continued revenue volatility increases reliance on partnerships or external funding and makes it harder to support research spending from internally generated operations.
Persistent UnprofitabilityDeep losses and negative gross profit demonstrate that the current business remains structurally investment-heavy rather than self-funding. Until development activities produce meaningful partnering or product economics, ongoing deficits can constrain strategic flexibility and require repeated financing.
Leverage And Cash BurnHigh leverage relative to equity, combined with substantial operating cash burn, leaves a limited balance-sheet cushion while losses continue. This combination can increase dependence on future capital raising and reduce the company’s ability to absorb setbacks in its development programs.
Alligator Bioscience AB News
7AL0 FAQ
What was Alligator Bioscience AB’s price range in the past 12 months?
Alligator Bioscience AB lowest stock price was <€0.01 and its highest was €0.09 in the past 12 months.
What is Alligator Bioscience AB’s market cap?
Alligator Bioscience AB’s market cap is €3.24M.
When is Alligator Bioscience AB’s upcoming earnings report date?
Alligator Bioscience AB’s upcoming earnings report date is Feb 11, 2027 which is in 108 days.
How were Alligator Bioscience AB’s earnings last quarter?
Alligator Bioscience AB released its earnings results on Oct 22, 2026. The company reported -€0.002 earnings per share for the quarter.
Is Alligator Bioscience AB overvalued?
According to Wall Street analysts Alligator Bioscience AB’s price is currently Overvalued.
Does Alligator Bioscience AB pay dividends?
Alligator Bioscience AB does not currently pay dividends.
What is Alligator Bioscience AB’s EPS estimate?
Alligator Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alligator Bioscience AB have?
Alligator Bioscience AB has 3,568,107,000 shares outstanding.
What happened to Alligator Bioscience AB’s price movement after its last earnings report?
Alligator Bioscience AB reported an EPS of -€0.002 in its last earnings report. Following the earnings report the stock price went down -53.191%.
Which hedge fund is a major shareholder of Alligator Bioscience AB?
Currently, no hedge funds are holding shares in DE:7AL0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alligator Bioscience AB
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its drug development. These include ALLIGATOR-GOLD and ALLIGATOR-FAB, an extensive human antibody library boasting roughly 60 billion distinct antibody fragments; FIND, a molecular evolution technique used for optimizing antibodies and other proteins; and RUBY, a specialized format for creating bispecific antibodies. Alligator Bioscience's pipeline features several promising candidates. In the clinical stage, Mitazalimab, an immunostimulatory CD40 antibody, has successfully completed Phase I trials for metastatic cancer. Also undergoing Phase I clinical evaluation is ATOR-1017, another immunostimulatory antibody designed to bind to the 4-1BB receptor on tumor-specific T cells. For its preclinical efforts, the company is advancing ALG.APV-527, a bispecific antibody targeting both 4-1BB and 5T4 for cancer therapy. Additionally, Alligator Bioscience holds an interest in the Biosynergy (AC101) project, which is currently in Phase I. To bolster its research and development capabilities, Alligator Bioscience has formed multiple strategic collaborations. It has a co-development partnership with Aptevo Therapeutics Inc. for ALG.APV-527, and a research alliance with MacroGenics, Inc. to create novel immunotherapies. Further collaborations include a joint research agreement with BioArctic AB (publ) to utilize proprietary antibody generation technologies for new product candidates, and a research and license agreement with Orion Corporation aimed at discovering and developing new bispecific antibody cancer therapeutics. The company was established in 2000.
Technical Analysis
BioInvent International AB
―
Oncopeptides AB
―
Elicera Therapeutics AB
―
Immunicum AB
―
Cantargia AB
―